Renovaro Inc (RENB) USD0.0001

Sell:$0.77Buy:$0.80$0.07 (8.20%)

Prices delayed by at least 15 minutes
Sell:$0.77
Buy:$0.80
Change:$0.07 (8.20%)
Prices delayed by at least 15 minutes
Sell:$0.77
Buy:$0.80
Change:$0.07 (8.20%)
Prices delayed by at least 15 minutes

Company Information

About this company

Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

Key people

David Weinstein
Chief Executive Officer, Director
Nathen Fuentes
Chief Financial Officer
Maurice van Tilburg
Independent Chairman of the Board
Douglas W. Calder
Independent Director
Mark Anthony Collins
Independent Director
James A. Mcnulty
Independent Director
Click to see more

Key facts

  • EPIC
    RENB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US29350E1047
  • Market cap
    $128.49m
  • Employees
    25
  • Shares in issue
    162.39m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.